Skip to main content

Table 1 Results of HIV molecular testing, Antigen/Antibody screening assay, and CD4 count from time first presentation (June 2014) to initiation of ARV therapy

From: Rapid development of HIV elite control in a patient with acute infection

Time Viral Load (RNA copies/ml) Forth Generation Antigen/Antibody HIV Test (s/co –relative quantity of HIV Ab) Confirmatory Test CD4+ T Cells/uL (%)
Viral Load SCA ARCHITECT (S/Co) VIDAS (S/Co) GS INNO-LIA  
Jun 2014 71550a 1 b NEG NEG
Oct 2014 <  200 11.1c 13.72c gp41 (3+), p31 (1+), p24 (3+), p17 (1+)c
Nov 2014 <  40 616 (45%)
Dec 2014
Oct 2015 <  40 459 (46%)
Apr 2016 <  40 558 (40%)
Sep 2016 0.84d
Antiretroviral therapy commenced September 2016d
Oct 16 585 (47%)
  1. SCA single copy assay, S/Co signal/cutoff
  2. Fourth Generation HIV Antigen/Antibody test: ARCHITECT® Abbott; VIDAS® BioMerieux; GS = GeneScreen® Bio-Rad
  3. INNO-LIA, Fujirebio®
  4. aRetrospective molecular test on stored sample from June 2014
  5. bRead as equivocal value at time of testing
  6. cPositive test
  7. dARV commenced on clinical grounds-patient presented with furunculosis